These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

316 related items for PubMed ID: 30715140

  • 21. A post-hoc analysis of serotype-specific vaccine efficacy of 13-valent pneumococcal conjugate vaccine against clinical community acquired pneumonia from a randomized clinical trial in the Netherlands.
    Gessner BD, Jiang Q, Van Werkhoven CH, Sings HL, Webber C, Scott D, Gruber WC, Grobbee DE, Bonten MJM, Jodar L.
    Vaccine; 2019 Jul 09; 37(30):4147-4154. PubMed ID: 31155413
    [Abstract] [Full Text] [Related]

  • 22. The impact of 13-valent pneumococcal conjugate vaccination on virus-associated community-acquired pneumonia in elderly: Exploratory analysis of the CAPiTA trial.
    Huijts SM, Coenjaerts FEJ, Bolkenbaas M, van Werkhoven CH, Grobbee DE, Bonten MJM, CAPiTA study team.
    Clin Microbiol Infect; 2018 Jul 09; 24(7):764-770. PubMed ID: 29050992
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Pneumonia with empyema among children in the first five years of high coverage with 13-valent pneumococcal conjugate vaccine.
    Syrogiannopoulos GA, Michoula AN, Tsimitselis G, Vassiou K, Chryssanthopoulou DC, Grivea IN.
    Infect Dis (Lond); 2016 Oct 09; 48(10):749-53. PubMed ID: 27320108
    [Abstract] [Full Text] [Related]

  • 25. Impact of the 13-valent pneumococcal conjugate vaccine on the incidences of community-acquired pneumonia and pneumonia-related hospitalizations in children ≤5 years after its implementation into the national immunization program of Turkey.
    Gönüllü E, Soysal A, Yıldız I, Aydemir G, Tunç T, Karaböcüoğlu M.
    Hum Vaccin Immunother; 2020 Oct 02; 16(10):2504-2508. PubMed ID: 32119602
    [Abstract] [Full Text] [Related]

  • 26. Effects of 13-valent pneumococcal conjugate vaccination of adults on lower respiratory tract infections and antibiotic use in primary care: secondary analysis of a double-blind randomized placebo-controlled study.
    van Werkhoven CH, Bolkenbaas M, Huijts SM, Verheij TJM, Bonten MJM.
    Clin Microbiol Infect; 2021 Jul 02; 27(7):995-999. PubMed ID: 32971253
    [Abstract] [Full Text] [Related]

  • 27. A systematic review of the burden of vaccine preventable pneumococcal disease in UK adults.
    Chalmers JD, Campling J, Dicker A, Woodhead M, Madhava H.
    BMC Pulm Med; 2016 May 11; 16(1):77. PubMed ID: 27169895
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Impact of universal pneumococcal vaccination on hospitalizations for pneumonia and meningitis in children in Montevideo, Uruguay.
    Pírez MC, Algorta G, Cedrés A, Sobrero H, Varela A, Giachetto G, Montano A.
    Pediatr Infect Dis J; 2011 Aug 11; 30(8):669-74. PubMed ID: 21407145
    [Abstract] [Full Text] [Related]

  • 31. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged ≥ 60 years: 3 years of follow-up in the CAPAMIS study.
    Ochoa-Gondar O, Vila-Corcoles A, Rodriguez-Blanco T, Gomez-Bertomeu F, Figuerola-Massana E, Raga-Luria X, Hospital-Guardiola I.
    Clin Infect Dis; 2014 Apr 11; 58(7):909-17. PubMed ID: 24532544
    [Abstract] [Full Text] [Related]

  • 32. Age-stratified burden of pneumococcal community acquired pneumonia in hospitalised Canadian adults from 2010 to 2015.
    LeBlanc J, ElSherif M, Ye L, MacKinnon-Cameron D, Ambrose A, Hatchette TF, Lang AL, Gillis HD, Martin I, Demczuk WH, LaFerriere C, Andrew MK, Boivin G, Bowie W, Green K, Johnstone J, Loeb M, McCarthy A, McGeer A, Semret M, Trottier S, Valiquette L, Webster D, McNeil SA.
    BMJ Open Respir Res; 2020 Mar 11; 7(1):. PubMed ID: 32188585
    [Abstract] [Full Text] [Related]

  • 33. Prevention of adult pneumococcal pneumonia with the 13-valent pneumococcal conjugate vaccine: CAPiTA, the community-acquired pneumonia immunization trial in adults.
    Isturiz R, Webber C.
    Hum Vaccin Immunother; 2015 Mar 11; 11(7):1825-7. PubMed ID: 26076136
    [Abstract] [Full Text] [Related]

  • 34. Effectiveness of 13-valent pneumococcal conjugate vaccine on radiological primary end-point pneumonia among cases of severe community acquired pneumonia in children: A prospective multi-site hospital-based test-negative study in Northern India.
    Awasthi S, Kohli N, Agarwal M, Pandey CM, Rastogi T, Pandey AK, Roy C, Mishra K, Verma N, Kumar CB, Jain PK, Yadav R, Dhasmana P, Chauhan A, Mohindra N, Shukla RC.
    PLoS One; 2022 Mar 11; 17(12):e0276911. PubMed ID: 36520841
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Change in Bacterial Causes of Community-Acquired Parapneumonic Effusion and Pleural Empyema in Children 6 Years After 13-Valent Pneumococcal Conjugate Vaccine Implementation.
    Madhi F, Levy C, Morin L, Minodier P, Dubos F, Zenkhri F, Dommergues MA, Mezgueldi E, Levieux K, Pneumonia Study Group , Béchet S, Varon E, Cohen R, GPIP (Pediatric Infectious Disease Group) .
    J Pediatric Infect Dis Soc; 2019 Nov 06; 8(5):474-477. PubMed ID: 30407519
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.